QANDLI DIABET KASALLIGI BILAN OG‘RIGAN BEMORLARDA GAPTOGLOBIN GENOTIPI VA YURAK-QON TOMIR KASALLIKLARI XAVFI BILAN BOG‘LIQ AHAMIYATI.
Keywords:
Kalit so‘zlar: 2-toifa qandli diabet, yurak-qon tomir kasalliklari, gaptoglobin, genotip, fenotip.Abstract
Annotatsiya: Gaptoglobin ( Hp) genetik jihatdan polimorf bo‘lib, uchta asosiy
genotipga ega: Hp 1-1, 2-1 va 2-2. Har bir genotip fenotipik jihatdan Hp tuzilishi va
uning asosiy funksiyasi-eski qizil qon hujayralaridan (eritrotsitlardan) bo‘shagan erkin
gemoglobinni (Hb) yo‘q qilish qobiliyati bilan farq qiladi. Qandli diabet bilan
kasallangan bemorlarda 2-2 genotip mavjud bo‘lsa, ularning yurak-qon tomir
kasalliklari xavfi boshqa genotiplar yoki diabet bo‘lmagan bemorlarga nisbatan yuqori
bo‘lishi mumkin. Bu xavf glyukozani nazorat qilish darajasi yomonlashganda yanada
oshadi. Ushbu xavfning aniq mexanizmi noma’lum bo‘lsa-da, bir nechta taklif qilingan
sabablar mavjud.
E vitamini diabetga chalingan va 2-2 genotipga ega bemorlarda yurak-qon tomir
hodisalarini kamaytirishi ko‘rsatilgan, ammo bunday terapiyani qo‘llashning
xavfsizligi hali noma’lum. Ilgari glyukozani agressivroq nazorat qilishning foyda va
xavflarini baholash uchun o'tkazilgan muhim tadqiqotning post-hoc tahlili shuni
ko‘rsatdiki, diabet bilan kasallangan va 2-2 genotipga ega bemorlarda yurak-qon tomir
xavfini kamaytiruvchi foyda mavjud bo‘lishi mumkin, bu boshqa genotipli bemorlarda
kuzatilmaydi.
Agar ushbu ma’lumot boshqa shunga o‘xshash muhim tadqiqotlarning post-hoc
tahlillari hamda glukagonga o‘xshash peptid agonistlari yoki natriy-glukoza
kotransporter ingibitorlari bilan o'tkazilgan yaqingi yurak-qon tomir xavfsizligi
tadqiqotlaridagi genotip farqlari bilan tasdiqlansa, bu klinitsistlarga yurak-qon tomir
hodisalariga eng ko‘p xavf ostida bo‘lgan bemorlarni aniqlash va ular uchun
glyukozani agressivroq nazorat qilish yoki boshqa antihiperglikemik vositalardan
foydalanish bo‘yicha eng samarali strategiyalarni belgilash imkonini beradi.
References
Adabiyotlar
1. American Diabetes Association. Cardiovascular disease and risk management:
Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl
1):S111-S134.
2. Costacou T, Levy AP. Haptoglobin genotype and its role in diabetic
cardiovascular disease. J Cardiovasc Transl Res. 2012;5(4):423-35.
3. MacKellar M, Vigerust DJ. Role of haptoglobin in health and disease: A focus
on diabetes. Clin Diabetes. 2016;34(3):148-57.
4. Asleh R, Levy AP. In vivo and in vitro studies establishing haptoglobin as a
major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag.
2005;1(1):19-28.
5. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin
polymorphism in humans. Clin Chem. 1996;42(10):1589-600.
6. Asleh R, Marsh S, Shilkrut M, et al. Genetically determined heterogeneity in
hemoglobin scavenging and susceptibility to diabetic cardiovascular disease.
Circ Res. 2003;92(11):1193-200.
7. Levy AP, Hochberg I, Jablonski K, et al. Haptoglobin phenotype is an
independent risk factor for cardiovascular disease in individuals with diabetes:
The strong heart study. J Am Coll Cardiol. 2002;40(11):1984-990.
8. Suleiman M, Aronson D, Asleh R, et al. Haptoglobin polymorphism predicts 30-
day mortality and heart failure in patients with diabetes and acute myocardial
infarction. Diabetes. 2005;54(9):2802-806.
9. Roguin A, Koch W, Kastrati A, et al. Haptoglobin genotype is predictive of
major adverse cardiac events in the 1-year period after percutaneous
transluminal coronary angioplasty in individuals with diabetes. Diabetes Care.
2003;26(9):2628-631.
10. Costacou T, Ferrell R, Orchard T. Haptoglobin genotype: A determinant of
cardiovascular complication risk in type 1 diabetes. Diabetes. 2008;57(6):1702-
706.
11. Cahill LE, Levy AP, Chiuve SE, et al. Haptoglobin genotype is a consistent
marker of coronary heart disease risk among individuals with elevated
glycosylated hemoglobin. J Am Coll Cardiol. 2013;61(7):728-37.
12. Cahill LE, Jensen MK, Chiuve SE, et al. The risk of coronary heart disease
associated with glycosylated hemoglobin of 6.5% or greater is pronounced in
the haptoglobin 2-2 genotype. J Am Coll Cardiol. 2015;66(16):1791-791.
13. Venerando B, Fiorilli A, Croci G, et al. Acidic and neutral sialidase in the
erythrocyte membrane of type 2 diabetic patients. Blood. 2002;99(3):1064-70.
14. Bamm VV, Tsemakhovich VA, Shaklai N. Oxidation of low-density lipoprotein
by hemoglobin hemichrome. Int J Biochem Cell Biol. 2003;35(3):349-58.
15. Asleh R, Guetta J, Kalet-Litman S, et al. Haptoglobin genotype- and diabetes-
dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ
Res. 2005;96(4):435-41.
16. Bamm VV, Tsemakhovich VA, Shaklai M, et al. Haptoglobin phenotypes differ
in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry.
2004;43(13):3899-906.
17. Asleh R, Blum S, Kalet-Litman S, et al. Correction of HDL dysfunction in
individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes.
2008;57(10):2794-800.
18. Rader DJ. Molecular regulation of HDL metabolism and function: implications
for novel therapies. J Clin Invest. 2006;116(12):3090-100.
19. Asleh R, Miller-Lotan R, Aviram M, et al. Haptoglobin genotype is a regulator
of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res.
2006;99(12):1419-425.
20. Azarov I, He X, Jeffers A, et al. Rate of nitric oxide scavenging by hemoglobin
bound to haptoglobin. Nitric Oxide. 2008;18(4):296-302.
21. Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular
hemolysis and extracellular plasma hemoglobin: a novel mechanism of human
disease. JAMA. 2005;293(13):1653-662.
22. Philippidis P, Mason JC, Evans BJ, et al. Hemoglobin scavenger receptor CD163
mediates Interleukin-10 release and Heme Oxygenase-1 synthesis:
Antiinflammatory monocyte-macrophage responses in vitro, in resolving skin
blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res.
2004;94(1):119-26.
23. Brown BG, Crowley J. Is there any hope for vitamin E? JAMA.
2005;293(11):1387-390.
24. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage
vitamin E supplementation may increase all-cause mortality. Ann Intern Med.
2005;142(1):37-46.
25. Hochberg I, Berinstein E, Milman U, et al. Interaction between the haptoglobin
genotype and Vitamin E on cardiovascular disease in diabetes. Curr Diab Rep.
2017;17(6):42.
26. Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Dagenais
G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-
risk patients. N Engl J Med. 2000;342(3):154-60.
27. Levy AP, Gerstein HC, Miller-Lotan R, et al. The effect of Vitamin E
supplementation on cardiovascular risk in diabetic individuals with different
haptoglobin phenotypes. Diabetes Care. 2004;27(11):2767.
28. Lee I, Cook N, Gaziano J, et al. Vitamin E in the primary prevention of
cardiovascular disease and cancer: The Women’s Health Study: A randomized
controlled trial. JAMA. 2005;294(1):56-65.
29. Blum S, Vardi M, Levy NS, et al. The effect of Vitamin E supplementation on
cardiovascular risk in diabetic individuals with different haptoglobin
phenotypes. Atherosclerosis. 2010;211(1):25-27.
30. Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces
cardiovascular events in a subgroup of middle-aged individuals with both type
2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-
blinded clinical trial. Arterioscler Thromb Vasc Biol. 2008;28(2):341-47.
31. Vardi M, Blum S, Levy AP. Haptoglobin genotype and cardiovascular outcomes
in diabetes mellitus—natural history of the disease and the effect of Vitamin E
treatment. Meta-analysis of the medical literature. Eur J Intern Med.
2012;23(7):628-32.
32. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC,
Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2
diabetes. N Engl J Med. 2008;358(24):2545-59.
33. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al.
Intensive blood glucose control and vascular outcomes in patients with type 2
diabetes. N Engl J Med. 2008;358(24):2560-72.
34. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular
complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-
39.
35. Carew AS, Levey AP, Ginsberg HN, et al. Haptoglobin phenotype modifies the
influence of intensive glycemic control on cardiovascular outcomes. J Am Coll
Cardiol. 2020;75(5):512-21.
36. Cefalu W, Kaul S, Gerstein H, et al. Cardiovascular outcomes trials in type 2
diabetes: where do we go from here? Reflections from a Diabetes Care editors’
expert forum. Diabetes Care. 2018;41(1):14-31.
